Medifast, Inc.
Consumer CyclicalNYSE:MED · New York Stock Exchange
-$0.03 today
Vol 0.10M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.4%
avg 42.9%
ROIC
-6.5%
avg 38.8%
ROA
-7.3%
avg 24.8%
Analysis
ROIC is currently the strongest return metric at -6.5% versus its period average of 38.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel R. Chard | Executive Chairman & Chief Executive Officer | $1.02M | — | 61 | $188,233.00 | 1.69% |
James Maloney | Chief Financial Officer | $727,968.00 | — | 58 | $73,033.00 | 0.66% |
Nicholas Johnson | CEO & President | $610,455.00 | — | 46 | $13,457.00 | 0.12% |
Jason L. Groves | Executive Vice President, General Counsel & Corporate Secretary | $591,987.00 | — | 55 | $21,697.00 | 0.20% |
Steven Zenker | Vice President of Investor Relations | — | — | — | — | — |
Claudia C. Greninger | Chief Human Resources Officer | — | — | 52 | — | — |
Jonathan Barrett MacKenzie | Vice President of Finance & Chief Accounting Officer | — | — | 54 | $20,838.00 | 0.19% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$246,677.11
Sells
0
$0.00
Net Sentiment
+$246,677.11
Net buying
Most Active
SCHLACKMAN SCOTT
2 transactions
Analysis
Insiders reported 4 buys worth $246,677.11 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $246,677.11. SCHLACKMAN SCOTT was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.7% | N/A1 analysts |
| Revenue | N/A | N/A | -8.6% | -0.5% (12yr)1 analysts |
| Net Income | N/A | N/A | +8.1% | N/A1 analysts |
| EBIT | N/A | N/A | +7.2% | -3.4% (12yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +12.7% over three years. Forward estimates point to Revenue at -0.5% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Torrid Holdings Inc.
NYSE:CURV
$197.01M
1stdibs.Com, Inc.
NASDAQ:DIBS
$144.16M
China Automotive Systems, Inc.
NASDAQ:CAAS
$139.39M
Bassett Furniture Industries, Incorporated
NASDAQ:BSET
$136.02M
Clarus Corporation
NASDAQ:CLAR
$119.17M
Kewaunee Scientific Corporation
NASDAQ:KEQU
$105.28M
MasterBeef Group
NASDAQ:MB
$103.44M
a.k.a. Brands Holding Corp.
NYSE:AKA
$95.23M
Robo.ai Inc.
NASDAQ:AIIO
$53.81M
Faraday Future Intelligent Electric Inc.
FFAI
$27.51M
Who manages MED?
Medifast, Inc. (MED) lists 7 active executives. The top listed executive is Daniel R. Chard, Executive Chairman & Chief Executive Officer.
Are MED insiders buying or selling?
Recent insider activity shows net selling of $9.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.